CareRx (FRA:29C1) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:29C1 CareRx Corp FRA:29C1
66 GF Score
Price €2.04
GF Value €1.37
! 3 Warning Signs
View Full Analysis

What is CareRx Defensive Interval Ratio?

FRA:29C1
66GF Score
CareRx Corp FRA:29C1
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CareRx (FRA:29C1) Overvalued in 2026?

Based on GuruFocus' analysis, CareRx stock appears to be overvalued. The current stock price of €2.04 is trading 48.9% above its estimated GF Value™ of €1.37.

Key valuation signals for FRA:29C1:

  • Defensive Interval Ratio:
  • GF Value™: €1.37 vs. price of €2.04 (48.9% above fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CareRx Business Description

Other Exchanges CHHHF:USACRRX:Canada
Address 320 Bay Street, Suite 1200, Toronto, ON, CAN, M5H 4A6
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
66GF Score

Get the complete analysis for FRA:29C1

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.04
Price
€1.37
GF Value